Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial - 11/01/21
Doi : 10.1016/j.jaad.2020.05.003
Joseph F. Merola, MD, MMSc a, Robert Sidbury, MD, MPH b, Andreas Wollenberg, MD c, Zhen Chen, PhD d, Annie Zhang, MD e, Brad Shumel, MD d, Ana B. Rossi, MD e, ⁎ 
a Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
b Seattle Children's Hospital, Seattle, Washington
c Ludwig-Maximilian University, Munich, Germany
d Regeneron Pharmaceuticals, Inc., Tarrytown, New York
e Sanofi Genzyme, Cambridge, Massachusetts
∗Correspondence to: Ana B. Rossi, MD, Sanofi Genzyme, 50 Binney St, Cambridge, MA 02142Sanofi Genzyme50 Binney StCambridgeMA02142
| ORCID: J.F.M., 0000-0001-6514-4353; R.S., 0000-0003-1522-4800; A.W., 0000-0003-0177-8722; A.B.R., 0000-0001-5345-678X. |
|
| Funding sources: Supported by Sanofi and Regeneron Pharmaceuticals, Inc. |
|
| Disclosure: Dr Merola is consultant and/or investigator for AbbVie, Aclaris, Almirall, Arena, Avotres, Biogen, Celgene, Dermavant, Eli Lilly, EMD Serono, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Sun Pharma, and UCB. Dr Sidbury is an investigator for Brickell Biotech, Pfizer, Regeneron Pharmaceuticals, Inc., and Scioderm; a continuing medical education participant in Medscape; and an advisory board member of Pfizer. Dr Wollenberg is an investigator for Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; is a consultant for Almirall, Anacor, Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme; and has received research grants from Beiersdorf, LEO Pharma, and Pierre Fabre. Drs Chen and Shumel are employees and shareholders of Regeneron Pharmaceuticals, Inc. Drs Zhang and Rossi are employees of and may hold stock and/or stock options in Sanofi Genzyme. |
|
| IRB approval status: Reviewed and approved by IRBs/ethics committees at all centers. |
|
| Author Contributions: ABR conceived the idea of the analyses described in this manuscript. ZC conducted the statistical analyses of the data. ABR drafted the manuscript with the medical writer. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript. |
|
| Reprints are not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. 495-497 - février 2021 Retour au numéro
Article précédent
- Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review
- Jiade Yu, Jennifer K. Chen, Christen M. Mowad, Margo Reeder, Sara Hylwa, Sarah Chisolm, Cory A. Dunnick, Ari M. Goldminz, Sharon E. Jacob, Peggy A. Wu, Jonathan Zippin, Amber Reck Atwater
- Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis
- Yu Wang, Solomon Geizhals, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?